Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Prof Carlos Morillo is a cardiac electrophysiologist, currently serving in the Chief Division of Cardiology at theLibin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada. Prof Morillo has extensively researched Chagas disease since 1990, and was involved in the initial studies related to autonomic control in the different stages of the disease and the use of beta… View more
Author(s): Roberto Keegan , Cynthia Yeung , Adrian Baranchuk Added: 3 years ago
Chagas disease is an important public health problem in Latin America. Almost 25% of the population (approximately 65 million individuals) are at risk of infection and another 6 million people are affected.1 However, migration and globalisation have resulted in the increased presence of Chagas disease worldwide, particularly in the US and Europe. Chagas disease is caused by a parasite, the… View more
Research Area(s) / Expertise:

Hypertension

Heart Failure

Emeritus Professor of Medicine - Cordoba National University Director - Instituto DAMIC-Fundación Rusculleda, Córdoba, Argentina Fellow of the European Society of Cardiology (FESC) Fellow of the American College of Cardiology (FACC) Past President - International Society of Cardiovascular Pharmacology DrFelipe Martínez is on the Editorial Board of European Cardiology Review. View more
Author(s): Mario Njeim , Frank Bogun Added: 3 years ago
Percutaneous ablation for ventricular tachycardia (VT) was first attempted in 1983 and has rapidly evolved to become an important option for controlling recurrent VTs.1 Endocardial ablation remained the only percutaneous approach until epicardial access was introduced by Sosa et al. in 1996 and thereafter became progressively more available as an adjunctive strategy for the treatment of… View more
Author(s): Federico Lombardi Added: 3 years ago
Atrial fibrillation (AF) is the most common clinical arrhythmia with a relevant socio-economic impact.1–3 Patients with atrial fibrillation are characterised by symptoms such as palpitations and shortness of breath; they have reduced exercise capacity and are subject to a higher risk of thromboembolic events. In spite of a relatively simple diagnosis, management of AF patients is difficult for… View more
Author(s): Ramanan Kumareswaran , Francis E Marchlinski Added: 3 years ago
Ventricular tachycardia (VT) is one of the most challenging medical conditions faced by cardiac patients and physicians treating them. Antiarrhythmic medications have limited effectiveness and are frequently poorly tolerated.1–4 Catheter ablation is increasingly used to treat patients successfully.1,5–7 Most VTs can be ablated endocardially but some require epicardial mapping and ablation… View more
Author(s): Deniz Akdis , Corinna Brunckhorst , Firat Duru , et al Added: 3 years ago
Arrhythmogenic cardiomyopathy (ACM) is usually referred to as arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).1A first historical description was made in 1736, whereas its first modern description dates back to 1982.2 Initially, ACM was thought to be an embryological malformation.3 Yet in recent years it became evident that the pathophysiology of an ongoing genetically… View more
Author(s): Adam J Graham , Michele Orini , Pier D Lambiase Added: 3 years ago
Recurrent episodes of ventricular tachycardia (VT) in patients with structural heart disease are associated with increased mortality and morbidity, despite the life-saving benefits of implantable cardiac defibrillators (ICDs).1,2 Because ICD therapies are abortive and do not alter the underlying arrhythmogenic substrate, their reduction becomes important, especially as recurrent shocks can cause… View more